Skip to main content

Table 1 Demographics of donors and recipients

From: rhErythropoietin-b as a tissue protective agent in kidney transplantation: a pilot randomized controlled trial

Donors (n = 34)
  rhEPO-b treated n = 19 Placebo n = 20
Demographics   
age (yrs) median(IQR) 52 (45-58) 53 (46-66)
male n (%) 10 (53%) 13 (65%)
ethnicity white n (%) 19 (100%) 20 (100%)
Cause of death n (%)   
intra-cranial
haemorrhage
14 (74%) 14 (70%)
other intra-cranial event 1 (5%) 4 (20%)
extra-cranial event 4 (21%) 2 (10%)
Donated kidney   
ECD kidney n (%) 7 (37%) 10 (50%)
DCD kidney n (%) 12 (63%) 10 (50%)
inotropic support n (%) 12 (63%) 16 (80%)
vasopressin n (%) 9 (47%) 11 (55%)
final creatinine (μmol/L) median(IQR) 61(51-87) 77(66-96)
warm ischaemic time1 mins (range) 17 (12-22) 17 (13-20)
DCD only
Recipients (n = 40)
Demographics   
age (yrs) median(IQR) 51 (43-63) 54 (41-63)
male n (%) 10 (53%) 14 (70%)
White 13 (68%) 19 (95%)
Asian 5 (27%) 1 (5%)
Afro-Caribbean 1 (5%) 0
BMI median(IQR) 25 (23-27) 25 (23-29)
Cause of ESRD n (%)   
glomerular disease 8 (42%) 6 (30%)
hypertension 1 (5%) 3 (15%)
reflux nephropathy 4 (21%) 3 (15%)
other 6 (32%) 8 (40%)
Mode of dialysis pre-transplant n (%)   
haemodialysis 9 (47%) 12 (60%)
peritoneal dialysis 8 (42%) 7 (35%)
pre-dialysis 2 (11%) 1 (5%)
months on dialysis median(IQR) 30 (16-51) 42 (22-52)
previous transplant n (%) 3 (16%) 5 (25%)
anuric pre-transplant n (%) 6 (32%) 7 (35%)
diabetes n (%) 1 (5%) 0
hypertension n (%) 17 (90%) 17 (85%)
rhEPO pre-transplant n (%) 17 (90%) 17 (85%)
days before transplant of last rhEPO median (IQR) 5 (4-11.5) 4.5 (1.8-11.0)
PRA%   
0-5 14 14
6-84 4 5
>84 1 1
HLA mismatches   
0 5 4
1-2 5 6
3-4 9 10
Cold ischaemic time hrs.mins (range) 16.52 16.45
(12.19-32.36) (11.12-28.42)
EPO maintenance post-transplant n(%) 9 (46%) 11 (55%)
Blood transfusions post-transplant (n) 6 11
Packed red cell post-transplant (units) 1.2 ± 0.5 1.9 ± 0.6
Acute rejection episodes in 3 mths post-transplant 5 3
  1. 1warm ischaemic time in DCD was defined as the time from asystole to in-situ cold perfusion.
  2. IQR = interquartile range, BMI = body mass index, ESRD = end stage renal disease, PRA = panel reactive antibodies.
\